Posted by Michael Wonder on 26 Aug 2025
Repatha now indicated for adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C
25 August 2025 - Amgen today announced that the US FDA has broadened the approved use of Repatha (evolocumab) to include adults at increased risk for major adverse cardiovascular events due to uncontrolled low-density lipoprotein cholesterol.
The update removes a prior requirement for a patient to have been diagnosed with cardiovascular disease.
